Kristin Stephens - Mar 31, 2024 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Chief Development Officer
Signature
/s/ Todd Rosenthal, as attorney-in-fact
Stock symbol
SYRS
Transactions as of
Mar 31, 2024
Transactions value $
-$21,596
Form type
4
Date filed
4/2/2024, 05:01 PM
Previous filing
Nov 2, 2023
Next filing
Nov 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SYRS Common Stock Options Exercise +2K +12.67% 17.8K Mar 31, 2024 Direct F1
transaction SYRS Common Stock Options Exercise +11.7K +65.58% 29.5K Mar 31, 2024 Direct F1
transaction SYRS Common Stock Tax liability -$21.6K -4.22K -14.32% $5.12 25.2K Apr 1, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRS Restricted Stock Units Options Exercise $0 -2K -33.33% $0.00 4K Mar 31, 2024 Common Stock 2K Direct F3, F4
transaction SYRS Restricted Stock Units Options Exercise $0 -11.7K -33.33% $0.00 23.3K Mar 31, 2024 Common Stock 11.7K Direct F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock received upon vesting of a restricted stock unit award.
F2 Represents shares used to cover tax withholding upon the release of restricted stock units.
F3 Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F4 Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023.
F5 Represents a restricted stock unit award granted on February 16, 2023. These restricted stock units vest in three equal annual installments commencing on March 31, 2024.